Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

Podcasts

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals More

Online First

September 14, 2020

Correspondence
Comparison of MS score and HScore for the diagnosis of adult-onset Still’s disease-associated macrophage activation syndrome
Free

Lei Zhang, Xiaopei Yang, Tian-Fang Li, Xiaojun Liu, Shengyun Liu

doi: 10.1136/annrheumdis-2020-217917

September 09, 2020

Correspondence response
Response to: ‘Correspondence on ‘Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences’ by Ruscitti et al’ by Chen et al
Free

Piero Ruscitti, Federico Bruno, Onorina Berardicurti, Chiara Acanfora, Viktoriya Pavlych, Pierpaolo Palumbo, Alessandro Conforti, Francesco Carubbi, Ilenia Di Cola, Paola Di Benedetto, Paola Cipriani, Davide Grassi, Carlo Masciocchi, Annamaria Iagnocco, Antonio Barile, Roberto Giacomelli

doi: 10.1136/annrheumdis-2020-218909
Correspondence
Tocilizumab for the treatment of polyarteritis nodosa: a systematic literature review
Free

Mitsuhiro Akiyama, Yuko Kaneko, Tsutomu Takeuchi

doi: 10.1136/annrheumdis-2020-218710
Correspondence response
Response to: ‘Tofacitinib for the treatment of polyarteritis nodosa: a literature review’ by Akiyama et al
Free

Doron Rimar, Abid Awisat, Lisa Kaly, Gleb Slobodin, Itzhak Rosner, Michael Rozenbaum, Shira Ginsberg, Elina Starosvetsky, Ayelet Alpert, Shai Shen-Orr

doi: 10.1136/annrheumdis-2020-218790
Correspondence
Correspondence on ‘Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences’ by Ruscitti et al
Free

Acer I-Hung Chen, Sheng-Chieh Lin, James Cheng-Chung Wei

doi: 10.1136/annrheumdis-2020-218876

September 07, 2020

Correspondence
Adherence to medication in patients with rheumatic diseases during COVID-19 pandemic
Free

Alireza Khabbazi, Hadiseh Kavandi, Roghayeh Paribanaem, Raha Khabbazi, Aida Malek Mahdavi

doi: 10.1136/annrheumdis-2020-218756
Correspondence response
Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: ‘Comment on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases’ by Giollo et al
Free

Kimme L Hyrich, Milena Gianfrancesco, Pedro M Machado, Jinoos Yazdany, Philip C Robinson

doi: 10.1136/annrheumdis-2020-218910
Correspondence response
Response to: ‘Implications of SARS-CoV-2 infection for patients with rheumatic disease’ by Lin et al
Free

Alexis Mathian, Zahir Amoura

doi: 10.1136/annrheumdis-2020-218404
Correspondence response
Education and treatment adherence during the COVID-19 pandemic. Response to: ‘Adherence to medication in patients with rheumatic diseases during COVID-19 pandemic’ by Khabbazi et al
Free

Rita Angélica Pineda-Sic, Griselda Serna-Peña, Jesus Alberto Cardenas-de la Garza, Sergio A Torres-Castillo, Dionicio Angel Galarza-Delgado, Diana Elsa Flores-Alvarado

doi: 10.1136/annrheumdis-2020-218791
Correspondence
Comment on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases
Free

Alessandro Giollo, Eugenia Bertoldo, Giovanni Adami, Adam J Cybulski, Angelo Fassio, Giovanni Orsolini, Luca Idolazzi, Davide Gatti, Ombretta viapiana, Maurizio Rossini

doi: 10.1136/annrheumdis-2020-218845

September 04, 2020

Correspondence
Management of immune checkpoint inhibitor-induced polymyalgia rheumatica
Free

Kornelis S M van der Geest, Maria Sandovici, Abraham Rutgers, T Jeroen N Hiltermann, Sjoukje F Oosting, Riemer H J A Slart, Elisabeth Brouwer

doi: 10.1136/annrheumdis-2020-218276

September 03, 2020

Correspondence response
Response to ‘Impact of COVID-19 pandemic on hospitalisation of patients with systemic lupus erythematosus (SLE): report from a tertiary hospital during the peak of the pandemic’ by Chuah et al
Free

Alexis Mathian, Zahir Amoura

doi: 10.1136/annrheumdis-2020-218487

September 01, 2020

Correspondence response
Response to: ‘Correspondence on ‘Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study’ by Potere et al’ by Buckley
Free

Nicola Potere, Marcello Di Nisio, Donatella Cibelli, Rosa Scurti, Antonella Frattari, Ettore Porreca, Antonio Abbate, Giustino Parruti

doi: 10.1136/annrheumdis-2020-218715
Correspondence
Correspondence on ‘Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study’ by Potere et al
Free

Leo Buckley

doi: 10.1136/annrheumdis-2020-218693
Correspondence
Impact of lockdown on rheumatology outpatient care in the age of COVID-19
Free

Benjamin Sachdev Manjit Singh, Seow Lin Chuah, Yaw Kiet Cheong, Sharifah Aishah Wan, Cheng Lay Teh

doi: 10.1136/annrheumdis-2020-218484
Correspondence response
Response to: ‘Do we need the PFAPA syndrome in adults with non-monogenic periodic fevers?’ by Fayand et al
Free

Marco Gattorno, Michael Hofer, Federica Vanoni, Silvia Federici, Luca Cantarini, Nicolino Ruperto for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Eurofever Registry

doi: 10.1136/annrheumdis-2019-216862
Correspondence response
Response to: ‘Comment on: ‘EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update’ by Gossec et al’ by Wei et al
Free

Laure Gossec, Xenofon Baraliakos, Iain McInnes, Andreas Kerschbaumer, Maarten de Wit, Maxime Dougados, Jette Primdahl, Désirée van der Heijde, Josef S Smolen

doi: 10.1136/annrheumdis-2020-218456
Correspondence
Comment on: ‘EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update’ by Gossec et al
Free

Chen-Yu Wei, Yung-Heng Lee, James Cheng Chung Wei

doi: 10.1136/annrheumdis-2020-218385

August 31, 2020

Correspondence
Rheumatic disease and COVID-19
Free

Jean W Liew, Elizabeth R Graef

doi: 10.1136/annrheumdis-2020-217674
Correspondence
Analysis on misdiagnosis of a case of novel variant of NLRP12
Free

Xiran Yang, Bo Zhao, Yabin Liao

doi: 10.1136/annrheumdis-2020-218422

August 28, 2020

Correspondence
Comment on ‘Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19’ by Konig et al. Long-term exposure to hydroxychloroquine or chloroquine and the risk of hospitalisation with COVID-19: a nationwide, observational cohort study in 54 873 exposed individuals and 155 689 matched unexposed individuals in France
Free

Emilie Sbidian, Laetitia Penso, Philippe Herlemont, Jérémie Botton, Bérangère Baricault, Laura Semenzato, Jérome Drouin, Alain Weill, Rosemay Dray-Spira, Mahmoud Zureik

doi: 10.1136/annrheumdis-2020-218647
Correspondence
Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine’ by Mathian et al
Free

Quirin Notz, Patrick Meybohm, Peter Kranke, Dirk Weismann, Christopher Lotz, Marc Schmalzing

doi: 10.1136/annrheumdis-2020-218778
Correspondence
Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials – a real-world district general hospital experience
Free

Asim Khan, Alice Cole, Naveen Bhadauria, Munzir El-Hassan, Daud Abdulla, Thomas Axon, Zozik Fattah, Jessica J Manson, Jeronimo Moreno-Cuesta, Dev Mukerjee

doi: 10.1136/annrheumdis-2020-218528
Correspondence
Systemic lupus erythematosus and COVID-19: what we know so far
Free

Giuseppe A. Ramirez, Luca Moroni, Emanuel Della-Torre, Maria Gerosa, Lorenzo Beretta, Enrica P. Bozzolo, Lorenzo Dagna

doi: 10.1136/annrheumdis-2020-218601

August 27, 2020

Correspondence response
Anti-inflammatory action of colchicine in hospitalised patients with COVID-19. Response to: ‘Colchicine treatment in community healthcare setting to prevent severe COVID-19’ by Della-Torre et al
Free

Silvia Piantoni, Enrico Colombo, Roberto Furloni, Laura Andreoli, Antonio Brucato, Massimo Imazio, Paolo Airó, Mirko Scarsi

doi: 10.1136/annrheumdis-2020-218806
Correspondence
Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still’s disease
Free

Piero Ruscitti, Tanja A Stamm, Roberto Giacomelli

doi: 10.1136/annrheumdis-2020-218032
Correspondence
Colchicine treatment in community healthcare setting to prevent severe COVID-19
Free

Emanuel Della-Torre, Giuseppe A Ramirez, Lorenzo Dagna, Moreno Tresoldi

doi: 10.1136/annrheumdis-2020-218759

August 21, 2020

Correspondence
Exaggerated neutrophil extracellular trap formation in Kawasaki disease: a key phenomenon behind the outbreak in western countries?
Free

Kouhei Yamashita, Akifumi Takaori-Kondo, Kiyomi Mizugishi

doi: 10.1136/annrheumdis-2020-218593
Correspondence
Case of postpartum axial spondyloarthritis
Free

Kazunori Furuhashi, Nanase Honda, Yuji Miyoshi, Naoto Yokogawa

doi: 10.1136/annrheumdis-2020-218587
Correspondence response
Response to: ‘Case of postpartum axial spondyloarthritis’ by Furuhashi et al
Free

Adel Hoballah, Cédric Lukas, Christophe Leplat, Patrice Taourel, Jean-Baptiste Pialat, Nicolas Sans, Sonia Ramos-Pascual, Mo Saffarini, Catherine Cyteval

doi: 10.1136/annrheumdis-2020-218687
Correspondence response
Response to: ‘Exaggerated neutrophil extracellular trap formation in Kawasaki disease: a key phenomenon behind the outbreak in western countries?’ by Yamashita et al
Free

Marie Pouletty, Glory Dingulu, Naim Ouldali, Olivier Corseri, Camille Ducrocq, Ulrich Meinzer, Albert Faye, Caroline Galeotti, Isabelle Melki Great Paris Region (GPR) Kawa-COVID-19 consortium

doi: 10.1136/annrheumdis-2020-218644
Correspondence
High risk of systemic lupus erythematosus development in patients with ITP: antiphospholipid syndrome is also a concern
Free

Murat İnanç, Bahar Artim-Esen, Reyhan Diz-Küçükkaya

doi: 10.1136/annrheumdis-2020-218345

August 19, 2020

Correspondence
Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis
Free

Mendel E Singer, David C Kaelber, Maria J Antonelli

doi: 10.1136/annrheumdis-2020-218500
Correspondence
Correspondence to: ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al
Free

Rachael Mary Flood, Richard Conway, Colm Kirby, Diana Gheta, David J Kane, Ronan H Mullan

doi: 10.1136/annrheumdis-2020-218733
Correspondence response
Response to: ‘High dosage of Methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to Tocilizumab’ by Conticini et al
Free

Sofia Ramiro, Rémy Mostard, Robert BM Landewé

doi: 10.1136/annrheumdis-2020-218788
Correspondence
Challenge of diagnosing ANCA-associated vasculitis during COVID-19 pandemic: a missed ‘window of opportunity’
Free

Alessandro Giollo, Riccardo Bixio, Davide Gatti, Ombretta Viapiana, Luca Idolazzi, Christian Dejaco, Maurizio Rossini

doi: 10.1136/annrheumdis-2020-218830
Correspondence
High dosage of methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to tocilizumab
Free

Edoardo Conticini, Federico Franchi, David Bennett, Serafina Valente, Maria A Mazzei, Elena Bargagli, Luca Volterrani, Sabino Scolletta, Bruno Frediani

doi: 10.1136/annrheumdis-2020-218761
Correspondence
Correspondence on: ‘Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation—an open-label cohort study’ by Della-Torre et al
Free

Chao Cheng, Fangjie Zhang

doi: 10.1136/annrheumdis-2020-218616
Correspondence response
Impact of sarilumab on mechanical ventilation in patients with COVID-19. Response to: ‘Correspondence on: ‘Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation–an open-label cohort study’ by Della-Torre et al’ by Cheng and Zhang
Free

Emanuel Della-Torre, Giovanni Landoni, Alberto Zangrillo, Lorenzo Dagna

doi: 10.1136/annrheumdis-2020-218724

August 18, 2020

Correspondence
Comment on: Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a patient with COVID-19 with psoriatic arthritis receiving ustekinumab
Free

Francesco Messina, Francesca Pampaloni, Stefano Piaserico

doi: 10.1136/annrheumdis-2020-218029
Correspondence response
Rheumatic diseases and COVID-19: a cohort of 17 patients under DMARDs. Response to: ‘Comment on: Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a COVID-19 patient with psoriatic arthritis receiving ustekinumab’ by Messina et al
Free

Pierre-Marie Duret, Lionel Spielmann, Laurent Messer

doi: 10.1136/annrheumdis-2020-218147

August 14, 2020

Correspondence
Tapering antirheumatic drugs in a resource-poor setting: real-world evidence
Free

Muhammad Haroon, Zara Khan, Maryam Aamer

doi: 10.1136/annrheumdis-2020-218703
Correspondence response
Response to: ‘Tapering antirheumatic drugs in a resource-poor setting: real-world evidence’ by Haroon et al
Free

Elise van Mulligen, Pascal H P de Jong

doi: 10.1136/annrheumdis-2020-218731

August 13, 2020

Correspondence
Implications of SARS-CoV-2 infection for patients with rheumatic disease
Free

Changsong Lin, Ziyu Wang, Jie Li, Xinyi Xia, Yun Liu, Qianghu Wang

doi: 10.1136/annrheumdis-2020-218050

August 12, 2020

Letter
COVID-19 and how evidence of a new disease evolves
Free

Féline P B Kroon, Ted R Mikuls, Robert BM Landewé

doi: 10.1136/annrheumdis-2020-218483
Correspondence response
COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: ‘Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials – a real-world district general hospital experience’ by Khan et al, ‘Comment on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry’ by Gianfrancesco M et al’ by Andreica et al and ‘COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs’ by Ansarin et al
Free

Milena Gianfrancesco, Kimme L Hyrich, Jinoos Yazdany, Pedro M Machado, Philip C Robinson

doi: 10.1136/annrheumdis-2020-218713

August 11, 2020

Correspondence
Impact of COVID-19 pandemic on hospitalisation of patients with systemic lupus erythematosus (SLE): report from a tertiary hospital during the peak of the pandemic
Free

Seow Lin Chuah, Cheng Lay Teh, Sharifah Aishah Wan Mohd Akbar, Yaw Kiet Cheong, Benjamin Sachdev Manjit Singh

doi: 10.1136/annrheumdis-2020-218475
Correspondence response
Response to: ‘Glucosamine and mortality: a note of caution’ by Conway
Free

Zhi-Hao Li, Qing-Mei Huang, Wen-Fang Zhong, Xi-Ru Zhang, Chen Mao

doi: 10.1136/annrheumdis-2020-218660
Correspondence
Glucosamine and mortality: a note of caution
Free

Richard Conway

doi: 10.1136/annrheumdis-2020-218489
Correspondence
COVID-19 infection in a patient with FMF: does colchicine have a protective effect?
Free

Senol Kobak

doi: 10.1136/annrheumdis-2020-217882

Log in using your username and password

Main menu

Log in using your username and password

You are here

Online First

September 14, 2020

September 09, 2020

September 07, 2020

September 04, 2020

September 03, 2020

September 01, 2020

August 31, 2020

August 28, 2020

August 27, 2020

August 21, 2020

August 19, 2020

August 18, 2020

August 14, 2020

August 13, 2020

August 12, 2020

August 11, 2020

Pages